We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent BioSolutions Inc. (EBS - Free Report) is a global specialty biopharmaceutical company that offer specialized products to health care providers and governments to fulfil unmet medical needs and combat emerging public health threats.
The company’s key Biodefense product BioThrax is marketed for the general use in both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. The U.S. government is the primary purchaser of the Biodefense products.
Emergent is also developing a next-generation anthrax vaccine candidate AV7909 for post-exposure prophylaxis of anthrax disease in a phase III study. The development and delivery of AV7909 is being funded by Biomedical Advanced Research and Development Authority (BARDA). The company has a multi-year contract worth about $1.6 billion with the BARDA for advanced development and delivery of AV7909. It secured the contract in 2016.
This apart, Emergent markets smallpox vaccine ACAM2000 and anthrax monoclonal antibody raxibacumab, both of which were acquired in the fourth quarter of 2017 from Sanofi (SNY - Free Report) and GlaxoSmithKline (GSK - Free Report) , respectively.
Notably, last October, Emergent added the Narcan (naloxone HCl) nasal spray to its portfolio following the acquisition of the privately held Adapt Pharma. The product has been performing impressively ever since and has made a significant contribution to the company’s top line.
Also, in the same month of 2018, Emergent acquired the specialty vaccine company PaxVax, which added two marketed vaccines, namely Vivotif (Typhoid Vaccine Live Oral Ty21a) and Vaxchora (Cholera Vaccine, Live, Oral) to its portfolio.
The acquisition of Adapt Pharma and PaxVax expanded Emergent’s presence in the public health threats market.
Meanwhile, Emergent is conducting several early-mid-stage studies on its vaccine candidates to address various ailments. The company is conducting a phase I study on VLA1601 (Zika virus vaccine) in partnership with Valneva. Emergent also completed enrollment in the phase II study on flu IGIV therapeutic for treating severe illness caused by influenza A infection in hospitalized patients with data expected in the first half of 2020.
Emergent is also evaluating the safety and immunogenicity of its chikungunya vaccine candidate CHIKV-VLP in a phase II study across a series of dosing regimens.
We remind investors that Emergent faces stiff competition from a number of companies with Biodefense products or candidates under development for both the U.S. government procurement and development resources. Moreover, in April 2019, Teva Pharmaceutical Industries Limited (TEVA - Free Report) received the FDA approval to market its generic version of Narcan nasal spray. If Teva launches this generic version, it might negatively impact Emergent’s growth and revenues in the future.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
Emergent BioSolutions Inc. (EBS - Free Report) is a global specialty biopharmaceutical company that offer specialized products to health care providers and governments to fulfil unmet medical needs and combat emerging public health threats.
The company’s key Biodefense product BioThrax is marketed for the general use in both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. The U.S. government is the primary purchaser of the Biodefense products.
Emergent is also developing a next-generation anthrax vaccine candidate AV7909 for post-exposure prophylaxis of anthrax disease in a phase III study. The development and delivery of AV7909 is being funded by Biomedical Advanced Research and Development Authority (BARDA). The company has a multi-year contract worth about $1.6 billion with the BARDA for advanced development and delivery of AV7909. It secured the contract in 2016.
This apart, Emergent markets smallpox vaccine ACAM2000 and anthrax monoclonal antibody raxibacumab, both of which were acquired in the fourth quarter of 2017 from Sanofi (SNY - Free Report) and GlaxoSmithKline (GSK - Free Report) , respectively.
Notably, last October, Emergent added the Narcan (naloxone HCl) nasal spray to its portfolio following the acquisition of the privately held Adapt Pharma. The product has been performing impressively ever since and has made a significant contribution to the company’s top line.
Also, in the same month of 2018, Emergent acquired the specialty vaccine company PaxVax, which added two marketed vaccines, namely Vivotif (Typhoid Vaccine Live Oral Ty21a) and Vaxchora (Cholera Vaccine, Live, Oral) to its portfolio.
The acquisition of Adapt Pharma and PaxVax expanded Emergent’s presence in the public health threats market.
Meanwhile, Emergent is conducting several early-mid-stage studies on its vaccine candidates to address various ailments. The company is conducting a phase I study on VLA1601 (Zika virus vaccine) in partnership with Valneva. Emergent also completed enrollment in the phase II study on flu IGIV therapeutic for treating severe illness caused by influenza A infection in hospitalized patients with data expected in the first half of 2020.
Emergent is also evaluating the safety and immunogenicity of its chikungunya vaccine candidate CHIKV-VLP in a phase II study across a series of dosing regimens.
We remind investors that Emergent faces stiff competition from a number of companies with Biodefense products or candidates under development for both the U.S. government procurement and development resources. Moreover, in April 2019, Teva Pharmaceutical Industries Limited (TEVA - Free Report) received the FDA approval to market its generic version of Narcan nasal spray. If Teva launches this generic version, it might negatively impact Emergent’s growth and revenues in the future.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>